Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00137423 · ClinicalTrials.gov registry record · Phase 2
Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer
A Phase 2 study of Carcinoma, Renal Cell Metastasis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
- 10
- Study locations
NCT00137423 is a Phase 2 study of Carcinoma, Renal Cell Metastasis that has completed, run by Pfizer. The registered enrollment target is 107 participants. The trial reports 10 study locations across 4 states.
The verdict
NCT00137423, a Phase 2 study of Carcinoma, Renal Cell Metastasis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
- 10
- Study locations
Study Summary
To evaluate the anti-tumor activity of SU011248 (sunitinib) in cytokine-refractory metastatic renal cell carcinoma (RCC) when administered in a continuous treatment regimen
Conditions Studied
Interventions
- DRUG SU011248 (sunitinib)
Study Locations (10)
Other
- Pfizer Investigational Site - Villejuif
- Pfizer Investigational Site - Berlin
- Pfizer Investigational Site - München
- Pfizer Investigational Site - Thessaloniki
- Pfizer Investigational Site - Lund
- Pfizer Investigational Site - Stockholm
- Pfizer Investigational Site - Sankt Gallen
California
- Pfizer Investigational Site - Stanford
Nevada
- Pfizer Investigational Site - Las Vegas
Gelderland
- Pfizer Investigational Site - Nijmegen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2005-05 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00137423
The ClinicalTrials.gov registry entry for NCT00137423 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Renal Cell Metastasis appearing as the primary indexed condition, and to 1 intervention - of which SU011248 (sunitinib) is the first listed.
NCT00137423 reports 10 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Nevada.
Frequently Asked Questions
What is clinical trial NCT00137423 about?
NCT00137423 is a clinical study titled "Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer". To evaluate the anti-tumor activity of SU011248 (sunitinib) in cytokine-refractory metastatic renal cell carcinoma (RCC) when administered in a continuous treatment regimen
What is the current status of trial NCT00137423?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2005-05. Estimated completion is 2008-05.
What conditions does trial NCT00137423 study?
This clinical trial studies the following conditions: Carcinoma, Renal Cell Metastasis.
What interventions are being tested in trial NCT00137423?
The interventions under investigation include: SU011248 (sunitinib) (DRUG).
Who is sponsoring clinical trial NCT00137423?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00137423 being conducted?
This trial has 10 study locations across California, Nevada, Gelderland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Renal Cell Metastasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.